All fields are required.
Rockwell Medical In The News
Medical Director Highlights Clinical and Economic Benefits with Triferic
March 18, 2018
AAKP features CEO Rob Chioini for the Innovator Series on Dialysis.
AAKP I January 2018
Pharmacokinetic of ferric pyrophosphate citrate, a novel iron salt, administered intravenously to health volunteers.
Journal of Clinical Pharmacology | August 2016
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
Drugs | April 18, 2016
Ferric pyrophosphate citrate (Triferic®) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients.
Nephrology Dialysis Transplantation | July 13, 2015
A Novel Approach to Giving Iron
Renal & Urology News | June 4, 2015
Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients.
Kidney International | May 14, 2015
Rockwell Medical’s innovative drug Triferic will impact iron deficiency therapy around the world.
Prosper Magazine | April 3, 2015
Kidney treatment breakthrough boosts Wixom firm.
The Detroit News | March 14, 2015
© 2018 Rockwell Medical